Newer Biological Agents in the Treatment of Severe Asthma: Real-World Results from a Tertiary Referral Center.
Adrenergic beta-Agonists
/ therapeutic use
Anti-Asthmatic Agents
Antibodies, Monoclonal, Humanized
/ therapeutic use
Asthma
/ drug therapy
Biological Products
/ therapeutic use
Disease Progression
Emergency Service, Hospital
/ statistics & numerical data
Female
Glucocorticoids
/ administration & dosage
Hospitalization
/ statistics & numerical data
Humans
Interleukin-5
/ antagonists & inhibitors
Male
Middle Aged
Muscarinic Antagonists
/ therapeutic use
Prednisone
/ administration & dosage
Receptors, Interleukin-5
/ antagonists & inhibitors
Retrospective Studies
Severity of Illness Index
Tertiary Care Centers
Treatment Outcome
Asthma
Drug therapy
Eosinophils
Immunology
Pharmacology
Journal
Lung
ISSN: 1432-1750
Titre abrégé: Lung
Pays: United States
ID NLM: 7701875
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
13
02
2020
accepted:
13
06
2020
pubmed:
26
6
2020
medline:
2
9
2021
entrez:
26
6
2020
Statut:
ppublish
Résumé
To determine the efficacy of IL-5 inhibitory therapy in severe, refractory asthma in a real-world clinical setting from a tertiary referral center. A retrospective chart review of patients with severe asthma treated with IL-5 biologic therapy for ≥ 6 months at Mayo Clinic in Rochester, Minnesota between January 1, 2013 and August 31, 2019. Over the study period, we identified 63 patients with a mean age of 54 who received an IL-5 inhibitor for ≥ 6 months. A total of 55 patients received mepolizumab, 2 received benralizumab, and 9 patients received both. Patients were followed up for a mean of 25 months. The mean number of months of oral prednisone use prior to biologic initiation was 64. There was a significant reduction in the median dose of prednisone in the 24 months after drug initiation (15 mg vs. 0 mg; p = < 0.0001). Similarly; there was a significant decline in the median number of asthma exacerbations in the 24 months before and after drug initiation (7 vs. 2; p = < 0.0001). The mean number of emergency room (ER) visits and hospitalizations decreased from 5.1 and 2.0 to 1.6 and 0.4 in the 24 months before and after therapy initiation (p < 0.0001 and p = 0.007, respectively) CONCLUSIONS: IL-5 inhibitory therapy is associated with significant and long-term sustained reductions in asthma exacerbation frequency, ER visits, hospitalizations, as well as oral steroid usage in a patient population with refractory steroid-dependent asthma referred to a tertiary referral center.
Identifiants
pubmed: 32583059
doi: 10.1007/s00408-020-00369-8
pii: 10.1007/s00408-020-00369-8
doi:
Substances chimiques
Adrenergic beta-Agonists
0
Anti-Asthmatic Agents
0
Antibodies, Monoclonal, Humanized
0
Biological Products
0
Glucocorticoids
0
Interleukin-5
0
Muscarinic Antagonists
0
Receptors, Interleukin-5
0
benralizumab
71492GE1FX
mepolizumab
90Z2UF0E52
Prednisone
VB0R961HZT
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM